Canada markets close in 3 hours 8 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
157.50+8.40 (+5.63%)
At close: 04:00PM EDT
156.55 -0.95 (-0.60%)
After hours: 07:56PM EDT
Sign in to post a message.
  • I
    ItsMeLayla
  • b
    bythepark
    Stephane Bancel disclosure in June 24th 8-K - "Bancel Stock Option and Charitable Giving" - Exercising 40,000 shares on Wednesday and 40,000 on Thursday each week, starting May 25, 2022, until the option is fully exercised around June 2023.
  • R
    Ryan
    Anyone watching FDA meeting from today? Please share updates if you are. Thank you.
  • B
    Burkhard
    who rembers the good old times (twice) when we doubled in a month?
  • C
    Cal
    As of 3/31/22, BNTX's working capital is 15.6 Billion Euros! Cash keeps flowing in, and not much flowing out! Absolutely mind boggling!
  • P
    Pathfinder
    Big presentation today at BioNTech.
    Lots of good news on cancer, CoVID and other infectious diseases.
    And "One More Thing" at pages 85 to 88 IMHO.
    Precision antibacterials - new Antibiotica.
  • I
    ItsMeLayla
    The German company is working on a type of synthetic antimicrobial called a ribolysin, which could be deployed against antibiotic-resistant bacteria, chief medical officer Ozlem Tureci said in a presentation to investors on Wednesday. The first patient trials of the platform should begin next year, CEO Ugur Sahin said.

    “The vision is to build a new category of precision antibacterials,” Sahin said. The technology could also allow doctors to target only dangerous bacteria, leaving the body’s natural microbiome intact, he said.

    BioNTech acquired an Austrian biotech, PhagoMed, with precision antibiotics technology last year. Antimicrobial resistance is one of the top 10 global killers, causing more than a million deaths annually, Tureci said.
  • M
    Midnite
    50% of a 3.2 billion dollar deal with another 6 billion option…up one percent after hours. It’s crazy how the market hates such a success story with such a bright future. 😂
  • d
    david
    FDA will use the BA.1 study to approve B.4 AND B.5 reformulated vaccine and animal tests . good news
  • G
    GR8
    The $3.2 billion contract, signed between the companies and the US health and defense departments, includes vaccines for babies, young children, teens and adults, and may include Omicron-specific vaccines, which a panel of government experts recommended on Tuesday.

    Delivery will begin in late summer and continue into the fourth quarter, the companies said. The contract gives the US the option to procure up to 300 million doses.
  • M
    Matthew
    Is Moderna getting a similar contract or has the US government picked a winner?
  • I
    ItsMeLayla
    The short interest in BioNtech is around $220 Million USD . This means we could see a shorts squeeze if we get a cascade of sign ups ranging from the EU Middle East. & China. God willing there is going to be a short squeeze!
  • R
    Ryan
    Coming this week, on Wednesday:
    BioNTech SE (Nasdaq: BNTX, “BioNTech” or the "Company”) will host the first edition of the Company’s Innovation Series on Wednesday, June 29th, 2022. The virtual event will provide an update on BioNTech’s clinical progress across its pipeline and provide a deep-dive on scientific and technology innovation from its proprietary research engine.
  • I
    ItsMeLayla
    BioNtech if there able to make a Universal Covid19 Vaccine the company will be worth $1,000/share
    Why?
    If the technology to actually trigger T cells is achieved for a universal Covid19 vaccine it means the following will occur:
    1. universal influenza vaccine
    2. Universal malaria Vaccine
    3. Universal Shingles Vaccine
    $1000/share
  • T
    Torsten
    Bryan Garnier left its rating on BioNTech at "buy" with a $296 price target in light of data presented on an Omikron vaccine.

    A vaccine specifically tailored to the Omikron variant has shown a better immune response than a broader-acting vaccine candidate, analyst Olga Smolentseva wrote in a research note issued Monday. In her view, the monovalent booster is therefore a more likely candidate for approval.

    Let's see if this happens today. Biontech is the only company with a monvalent booster candidate.
  • M
    Meili
    Expanding opportunities in infectious diseases:
    4 first-in-human mRNA vaccine trial starts expected in 2022

    Urgent need for next-generation precision antibacterials
    Page 85

    https://investors.biontech.de/static-files/edee73bd-1620-4f51-a419-7ce7782ffa0f
  • F
    Faramarz
    Folks, do you know which country would be best candidate for new omicron vaccine? It is China. Given its very low protection that they have (i.e., having low prior infection and low vaccination because people do not trust their government advocating domestic vaccine). Thus far, they have been locking down the cities… This is a wild guess but i think if by Fall, that is when Xi will be getting another term, China domestic mrna based omicron vaccine fails, they likely will come to Fosun and BioNTech to provide the vaccine. They cannot keep economy hurting until they found their own mRNA vaccine. Their government will get pressure from people to open to the Foreign vaccine. Back in spring, when things were bad in China, Shanghai governor throw in the idea of using foreign mrna vaccine….
  • c
    comirnaty2021
    Following the vote, and striving to use the best available scientific evidence, we have advised manufacturers seeking to update their COVID-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022.

    As we expect this coming year to be a transitional period when this modified booster vaccine may be introduced, we have not advised manufacturers to change the vaccine for primary vaccination, since a primary series with the FDA-authorized and approved COVID-19 vaccines provides a base of protection against serious outcomes of COVID-19 caused by circulating strains of SARS-CoV-2.

    Vaccine manufacturers have already reported data from clinical trials with modified vaccines containing an omicron BA.1 component and we have advised them that they should submit these data to the FDA for our evaluation prior to any potential authorization of a modified vaccine containing an omicron BA.4/5 component. Manufacturers will also be asked to begin clinical trials with modified vaccines containing an omicron BA.4/5 component, as these data will be of use as the pandemic further evolves.
  • I
    ItsMeLayla
    BA4-5 upgrades with better T cell response is required NOT just antibodies
    Currently 3,272 COVID patients are in hospitals across Australia, according to figures reported so far on Saturday.

    Authorities have warned of a third COVID-19 wave, driven by two new variants BA.4 and BA.5, which was expected to put pressure on the health system.

    Earlier this week, Dr Gerrard said we were entering a "different phase" of the pandemic.

    "There will be ongoing waves with new variants going on for months, or even years, and the era of public health directions is coming to an end," he said.

    Dr Gerrard said people over the age of 65, and those who are immunocompromised, should get a fourth dose of a COVID-19 vaccine, as it prevents severe illness and hospital admission.
  • I
    Investorgate
    Trust science, but most of all trust the geniuses of Biontech!